Innovent Biologics Phase 3 STAR Study Shows Efdamrofusp Alfa Effective In NAMD

AI Briefing

• – Innovent Biologics' efdamrofusp alfa injection shows effectiveness in treating nAMD.
• – The Phase 3 STAR study achieved its 52-week primary endpoint.
• – Efdamrofusp alfa injection demonstrates potential as a treatment for neovascular age-related macular degeneration.